| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | August 11, 2025 |
| Accession Number: | 0001213900-25-073704 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | August 11, 2025 |
| Accession Number: | 0001213900-25-073704 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/24/2024 | $8.50 | Buy | Ascendiant Capital Markets |
White Bear Lake, Minnesota--(Newsfile Corp. - July 31, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the second quarter ended June 30, 2025, as well as other subsequent events.Financial and Corporate Highlights for Second Quarter and to date:Strong momentum continues in the pivotal clinical trial of its investigational novel hearing device, the fully implanted Acclaim® cochlear implant.Successful activation of all 10 study participants' fully implanted Acclaim® cochlear implants in the first stage of the Company's pivotal clinical trial. A
White Bear Lake, Minnesota--(Newsfile Corp. - July 8, 2025) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the issuance of two new patents, further strengthening its intellectual property portfolio in the United States.The U.S. Patent & Trademark Office has issued two additional patents to Envoy Medical:U.S. Patent No. 12,318,607, on June 3, 2025. The title of the patent is Implantable Cochlear System with Integrated Components and Lead Characterization. Aspects of this patent relate to methods of compensating for variability in a middle ear sensor. Input signals from a middl
White Bear Lake, Minnesota--(Newsfile Corp. - July 1, 2025) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the issuance of three new patents, further strengthening its intellectual property portfolio in Australia.The Australian Patent Office has issued the following three patents to Envoy Medical Corporation:Australian Patent No. 2021391396 on April 24, 2025. The title of the patent is Implantable Cochlear Implant Stimulation Calibration. This patent relates to cochlear implant systems having a testing circuit that determines an amount of current provided by a source element
4 - Envoy Medical, Inc. (0001840877) (Issuer)
4 - Envoy Medical, Inc. (0001840877) (Issuer)
4 - Envoy Medical, Inc. (0001840877) (Issuer)
EFFECT - Envoy Medical, Inc. (0001840877) (Filer)
POS AM - Envoy Medical, Inc. (0001840877) (Filer)
10-Q - Envoy Medical, Inc. (0001840877) (Filer)
Ascendiant Capital Markets initiated coverage of Envoy Medical with a rating of Buy and set a new price target of $8.50
4 - Envoy Medical, Inc. (0001840877) (Issuer)
3 - Envoy Medical, Inc. (0001840877) (Issuer)
4 - Envoy Medical, Inc. (0001840877) (Issuer)
SC 13G - Envoy Medical, Inc. (0001840877) (Subject)
SC 13G - Envoy Medical, Inc. (0001840877) (Subject)
White Bear Lake, Minnesota--(Newsfile Corp. - July 31, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the second quarter ended June 30, 2025, as well as other subsequent events.Financial and Corporate Highlights for Second Quarter and to date:Strong momentum continues in the pivotal clinical trial of its investigational novel hearing device, the fully implanted Acclaim® cochlear implant.Successful activation of all 10 study participants' fully implanted Acclaim® cochlear implants in the first stage of the Company's pivotal clinical trial. A
Company Provides Update on Its Pivotal Clinical Study for Fully Implanted Cochlear ImplantWhite Bear Lake, Minnesota--(Newsfile Corp. - May 1, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the first quarter ended March 31, 2025, as well as other subsequent events.Financial and Corporate Highlights for First Quarter and to date:Secured additional $10 Million in funding to advance Pivotal Clinical Trial. Completed Enrollment of 10 participants in "first stage" of Pivotal Clinical Trial of the fully implanted Acclaim® cochlear implant.Activat
Company Provides Corporate Update that Includes Information on its Progress Enrolling Subjects in its Pivotal Clinical Study for Breakthrough Device, the Fully Implanted Acclaim® Cochlear ImplantWhite Bear Lake, Minnesota--(Newsfile Corp. - March 31, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the fourth quarter and full year ended December 31, 2024, as well as other subsequent events.Brent Lucas, CEO of Envoy Medical commented: "Envoy Medical had a successful 2024 and we are off to a wonderful start in 2025. Obtaining FDA's approval to
WHITE BEAR LAKE, Minn., June 11, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH) today announced the appointment of Michael Crowe to the Envoy Medical Board of Directors effective June 7, 2024. Envoy Medical is currently sponsoring an Early Feasibility Study at Mayo Clinic in Rochester, Minnesota for its investigational fully implanted Acclaim® Cochlear Implant. Envoy Medical expects to begin a larger pivotal clinical study for its device later in 2024. Mr. Crowe, who received his BS in Electrical Engineering from the University of Louisville and his MBA from Duke University, has decades of experience helping companies grow operations quickly and efficiently
Analyst Hosted Event to Feature Comprehensive Discussion of Envoy Medical's Products, Interviews with Two Study Investigators and Key Opinion Leaders in Cochlear Implants WHITE BEAR LAKE, Minnesota, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a revolutionary hearing health company focused on fully implanted hearing systems, today announced that it will host a fireside chat event on Thursday December 7, 2023 beginning at noon Central Time. The event will be hosted by a covering research analyst and feature interactive Q&A with Brent T. Lucas, Chief Executive Officer, and David R. Wells, Chief Financial Officer. Additionally, the Company